M.J. Flor

551 total citations
14 papers, 224 citations indexed

About

M.J. Flor is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, M.J. Flor has authored 14 papers receiving a total of 224 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in M.J. Flor's work include Lung Cancer Research Studies (5 papers), Cancer therapeutics and mechanisms (3 papers) and Lung Cancer Treatments and Mutations (3 papers). M.J. Flor is often cited by papers focused on Lung Cancer Research Studies (5 papers), Cancer therapeutics and mechanisms (3 papers) and Lung Cancer Treatments and Mutations (3 papers). M.J. Flor collaborates with scholars based in Spain, United States and Italy. M.J. Flor's co-authors include Luis Paz‐Ares, Enriqueta Felip, Ki Hyeong Lee, Isabelle Dussault, Tae Min Kim, Byoung Chul Cho, Rosa Álvarez, Laureen S. Ojalvo, James L. Gulley and Christoph Helwig and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of Thoracic Oncology.

In The Last Decade

M.J. Flor

11 papers receiving 220 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M.J. Flor Spain	6	162	73	58	47	22	14	224
Diego Enrico Argentina	8	136 0.8×	45 0.6×	42 0.7×	64 1.4×	7 0.3×	29	215
Amelia Sawyers United States	5	259 1.6×	49 0.7×	45 0.8×	66 1.4×	43 2.0×	8	316
Meixuan Chen United States	8	170 1.0×	87 1.2×	47 0.8×	54 1.1×	17 0.8×	10	268
Jayhyun Seo United States	5	152 0.9×	31 0.4×	24 0.4×	63 1.3×	15 0.7×	7	214
Kim Ryan Australia	3	225 1.4×	49 0.7×	29 0.5×	61 1.3×	15 0.7×	5	335
Marisa Flavin United States	5	156 1.0×	79 1.1×	97 1.7×	24 0.5×	26 1.2×	9	217
Javier Baena Spain	6	118 0.7×	19 0.3×	28 0.5×	34 0.7×	19 0.9×	18	168
Muhammad Junaid Tariq United States	8	120 0.7×	66 0.9×	42 0.7×	12 0.3×	29 1.3×	42	280
Davide Soldato Italy	10	192 1.2×	32 0.4×	50 0.9×	94 2.0×	16 0.7×	27	303
Nancy N. Chang United States	8	183 1.1×	162 2.2×	54 0.9×	155 3.3×	24 1.1×	37	353

Countries citing papers authored by M.J. Flor

Since Specialization

Citations

This map shows the geographic impact of M.J. Flor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.J. Flor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.J. Flor more than expected).

Fields of papers citing papers by M.J. Flor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.J. Flor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.J. Flor. The network helps show where M.J. Flor may publish in the future.

Co-authorship network of co-authors of M.J. Flor

This figure shows the co-authorship network connecting the top 25 collaborators of M.J. Flor. A scholar is included among the top collaborators of M.J. Flor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.J. Flor. M.J. Flor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Docampo, Lara Iglesias, Ana Maseda, Pedro Pérez Segura, et al.. (2024). 871P Randomized phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) unable for cisplatin (CP)-based chemotherapy (CT): NIVOTAX TTCC study. Annals of Oncology. 35. S624–S624.

Ponce-Aix, Santiago, Gregory M. Coté, Alejandro Falcón, et al.. (2021). OA11.04 Lurbinectedin With Irinotecan in Relapsed Small Cell Lung Cancer. Results From the Expansion Stage of a Phase I-II Trial. Journal of Thoracic Oncology. 16(3). S127–S127. 11 indexed citations

Paz‐Ares, Luis, David Vicente, Enriqueta Felip, et al.. (2020). 1272P Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC). Annals of Oncology. 31. S822–S822. 1 indexed citations

Paz‐Ares, Luis, Tae Min Kim, David Vicente, et al.. (2020). Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. Journal of Thoracic Oncology. 15(7). 1210–1222. 154 indexed citations

Aix, Santiago Ponce, Gregory M. Coté, Alejandro Falcón, et al.. (2020). Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors: Updated results from a phase Ib-II trial.. Journal of Clinical Oncology. 38(15_suppl). 3514–3514. 12 indexed citations

Flor, M.J., et al.. (2020). DIREITO E ARTE: LITERATURA, CINEMA E INTERDISCIPLINARIDADE.

Cho, Byoung Chul, Tae Min Kim, David Vicente, et al.. (2020). Two-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 38(15_suppl). 9558–9558. 6 indexed citations

Ponce, Santiago, Emiliano Calvo, Maria J. de Miguel, et al.. (2019). P2.12-13 Lurbinectedin (L) Combined with Paclitaxel (P) or Irinotecan (I) in Relapsed SCLC. Results from Two Phase Lb Trials. Journal of Thoracic Oncology. 14(10). S817–S817. 3 indexed citations

Flor, M.J., Alejandro Falcón, Gregory M. Coté, et al.. (2019). Lurbinectedin (LUR) in combination with irinotecan (IRI) in patients (pts) with advanced solid tumours. Annals of Oncology. 30. v178–v178. 3 indexed citations

10.

García, Jose Huygens Parente, et al.. (2017). Exercise Capacity and Respiratory Profile in Patients after Orthopedic Liver Transplantation: a Follow-up Study. Annals of Hepatology. 17(1). 98–103. 4 indexed citations

11.

Garcia, José Huygens Parente, et al.. (2017). Multi-professional team's perception of nurses' competences in liver transplantations. Revista Brasileira de Enfermagem. 70(2). 242–248. 14 indexed citations

12.

Flor, M.J., et al.. (2016). Pharmaceutical orientation at hospital discharge of transplant patients: strategy for patient safety. Einstein (São Paulo). 14(3). 359–365. 14 indexed citations

13.

Muro, Xavier García del, Antonio López–Pousa, M.J. Flor, et al.. (2012). Phase II study of neoadjuvant high-dose ifosfamide with concurrent radiotherapy followed by surgical resection in high-risk soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study.. Journal of Clinical Oncology. 30(15_suppl). 10052–10052. 2 indexed citations

14.

Flor, M.J. & José Miguel Cisneros. (2005). Insuficiencia respiratoria aguda en paciente tratado con infliximab. Enfermedades Infecciosas y Microbiología Clínica. 23(8). 503–504.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact